Macleods Pharmaceuticals Limited IPO

Macleods Pharmaceuticals Limited IPO has been filed with the capital market regulator SEBI for Rs.5,000 crore. This is going to be the second most IPO that has been raised by a Pharma after Gland’s Pharma Rs.6,480 Cr issue. Macleods Pharmaceuticals Limited is one of the seventh-largest drug pharma companies in the Indian Pharmaceutical Market.

Established in 1989, Macleods Pharmaceuticals are into developing, manufacturing and marketing an extensive range of pharmaceutical products. Their product portfolio includes the major therapeutic areas like anti-infectives, cardiovascular, dermatology, hormone treatment, etc. The brand has the highest number of WHO prequalified products globally with 65 registrations.

The brand has an extensive presence across the globe. Macleods Pharmaceuticals is present in more than 170 countries such as Africa, Europe, Asia, North America, etc. In India, the operations are supported by eight manufacturing units. The 8 manufacturing units have a vast range of oral dosage forms and complex formulations, such as topicals, injectables and inhalers.

Opening Date

To be announced

Closing Date

To be announced

Price Band

To be announced

Issue Size

To be announced

Face Value

To be announced

Market Lot

To be announced

Listing at NSE, BSE

IPO Open Date	To be announced
IPO Close Date	To be announced
Allotment Date	To be announced
Initiation Of Refunds	To be announced
Credit Of Shares To Demat Account	To be announced
IPO Listing Date	To be announced
UPI Mandate Expiry Date	To be announced

Particulars	2019	2020	2021
Revenue from operations	58,704.35	69,028.16	71,994.16
India	35,168.28	39,281.75	37,245.16
Outside India	23,536.07	29,746.41	34,749.00
EBITDA	13,408.93	17,243.18	20,966.60
EBITDA Margin	22.84%	24.98%	29.12%
PAT	11,921.30	14,611.95	16,307.18
PAT Margin	20.31%	21.17%	22.65%
ROCE	58.68%	65.49%	66.05%
Fixed Asset Turnover	6.10	6.68	5.69

Know before investing

Strengths

The brand has a strong R&D resulting in an amazing track record of product innovation and product launches

Their in-house packaging material unit helps the company in quality checks and quality control across the various stages of operations.

The company has an experienced and professional management team that helps in building brands

The company is one of the leading and fastest-growing companies, being among the top 10 Indian pharmaceutical companies

The company has a diversified presence across the global market existing in 170 countries

Risks

Any shortfall of raw materials or an increase of price, may affect the business

Any pharma manufacturers are subject to significant regulatory scrutiny. The introduction of any law from the regulatory bodies can impact the business adversely.

Changes in government regulation can affect the business

As the brand is dependent on third-party manufacturers, any delays or disruptions in the manufacturing facilities will affect the business

As the brand is heavily dependent on R&D, any setback in the department can affect the company